Mobia Medical (NASDAQ:MOBI) Director Purchases $184,472.86 in Stock

Mobia Medical, Inc. (NASDAQ:MOBI – Get Free Report) Director Casey Tansey acquired 15,821 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were bought at an average price of $11.66 per share, for a total transaction of $184,472.86. Following the acquisition, the director owned 284,725 shares of the company’s stock, valued at approximately $3,319,893.50. This represents a 5.88% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Mobia Medical Stock Down 2.6%

Shares of NASDAQ:MOBI opened at $11.42 on Thursday. Mobia Medical, Inc. has a 52-week low of $10.19 and a 52-week high of $15.29. The company has a debt-to-equity ratio of 0.04, a quick ratio of 12.80 and a current ratio of 13.28. The stock has a market capitalization of $380.17 million and a PE ratio of -0.59. The business has a 50-day moving average price of $12.38.

Get Mobia Medical alerts:

Mobia Medical (NASDAQ:MOBI – Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($1.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.27). The firm had revenue of $13.51 million for the quarter. The firm’s revenue for the quarter was up 102.4% on a year-over-year basis. As a group, equities analysts anticipate that Mobia Medical, Inc. will post -2.76 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Weiss Ratings started coverage on Mobia Medical in a research note on Wednesday, August 12th. They set a “sell (e-)” rating for the company. Wall Street Zen upgraded shares of Mobia Medical from a “sell” rating to a “hold” rating in a research note on Sunday, June 14th. JPMorgan Chase & Co. increased their price target on shares of Mobia Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. The Goldman Sachs Group initiated coverage on Mobia Medical in a research report on Tuesday, June 2nd. They set a “buy” rating and a $31.00 price target on the stock. Finally, BTIG Research reiterated a “buy” rating and issued a $19.00 target price on shares of Mobia Medical in a research report on Wednesday, August 12th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Mobia Medical has an average rating of “Moderate Buy” and a consensus price target of $20.75.

Check Out Our Latest Report on Mobia Medical

About Mobia Medical

(Get Free Report)

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.

Recommended Stories

• Five stocks we like better than Mobia Medical
• Bloom Energy’s AI Surge Meets a Valuation Reality Check
• Target Is Winning Shoppers Back—Can the Rally Reach $180?
• IonQ’s Space Contract Points to a New Frontier for Quantum Investors
• Is Apple’s AI Strategy Smarter Than Skeptics Think?

Receive News & Ratings for Mobia Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mobia Medical and related companies with MarketBeat.com's FREE daily email newsletter.